Terms: = Thyroid cancer AND MSH6, GTBP, P52701, 2956, ENSG00000116062, HSAP, HNPCC5 AND Treatment
3 results:
1. Clinical Characteristics and Responses to Immune Checkpoint Inhibitors in RET-Aberrant Digestive Tract Tumours.
Yen CC; Yeh YM; Huang HY; Ting YL; Fu PA; Lin TC; Liu IT; Yen CJ
Target Oncol; 2023 Jul; 18(4):611-623. PubMed ID: 37347391
[TBL] [Abstract] [Full Text] [Related]
2. Correlation of mismatch repair deficiency with clinicopathological features and programmed death-ligand 1 expression in thyroid carcinoma.
Qiao PP; Tian KS; Han LT; Ma B; Shen CK; Zhao RY; Zhang Y; Wei WJ; Chen XP
Endocrine; 2022 Jun; 76(3):660-670. PubMed ID: 35366156
[TBL] [Abstract] [Full Text] [Related]
3. Germline TP53 and msh6 mutations implicated in sporadic triple-negative breast cancer (TNBC): a preliminary study.
Yi D; Xu L; Luo J; You X; Huang T; Zi Y; Li X; Wang R; Zhong Z; Tang X; Li A; Shi Y; Rao J; Zhang Y; Sang J
Hum Genomics; 2019 Jan; 13(1):4. PubMed ID: 30630526
[TBL] [Abstract] [Full Text] [Related]
